ArticleCritical care explorations2020
Albumin Use After Cardiac Surgery.
Article in Critical care explorations, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Effect of 5% albumin on endothelial glycocalyx degradation during off-pump coronary artery bypass.Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2024Trial
- Addressing key considerations in the use of 20% human albumin for fluid resuscitation in cardiac surgery. Author's reply.Intensive care medicine · 2024Article
- Perioperative fluid management for adult cardiac surgery: network meta-analysis pooling on twenty randomised controlled trials.Perioperative medicine (London, England) · 2024Article
- Reduce intraoperative albumin utilisation in cardiac surgical patients: a quality improvement initiative.BMJ open quality · 2024Article
- Albumin use in bleeding cardiac surgical patients and associated patient outcomes.Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2021Article
- Albumin in adult cardiac surgery: a narrative review.Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2021Review
- Evaluation of the Safety and Efficacy of a Novel Thrombin Containing Combination Hemostatic Powder Using a Historical Control.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the effect of albumin exposure in ICU after cardiac surgery on hospital mortality, complications, and costs.
designA retrospective, single-center cohort study with economic evaluation.
settingCardiothoracic ICU in Australia. PATIENTS: Adult patients admitted to the ICU after cardiac surgery.
interventionsNone. MEASUREMENTS AND MAIN
resultsComparison of outcomes and costs in ICU after cardiac surgery based on 4% human albumin exposure. During the study period, 3,656 patients underwent cardiac surgery. After exclusions, 2,594 patients were suitable for analysis. One-thousand two-hundred sixty-four (48.7%) were exposed to albumin and 19 (1.4%) of those died. The adjusted hospital mortality of albumin exposure compared with no albumin was not significant (odds ratio, 1.24; 95% CI, 0.56-2.79;
conclusionsThere is no increased mortality in patients who are exposed to albumin after cardiac surgery. The patients exposed to albumin had higher illness severity, suffered more complications, and incurred higher healthcare costs. A randomized controlled trial is required to determine whether albumin use is effective and safe in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.